Mitazalimab shows promising survival rates in cancer study

Updated data from phase 2 study reveals survival benefit

Alligator Bioscience has announced updated results from its phase 2 OPTIMIZE-1 study, showing the survival benefits of mitazalimab in combination with standard chemotherapy (mFOLFIRINOX) for metastatic pancreatic cancer. The 24-month analysis of the 900 µg/kg dose demonstrates a significant survival benefit.

The data shows a 24-month survival rate of 29.4% for patients treated with mitazalimab combined with mFOLFIRINOX, compared to 8% for FOLFIRINOX alone, and 20% for NALIRIFOX alone. Median follow-up duration was 25.4 months, with 28% of patients still alive and 9% still on treatment.

Median overall survival in the study was 14.9 months, compared favourably to the 11.1 months for FOLFIRINOX and NALIRIFOX. The duration of response was confirmed at 12.6 months, compared to 5.9 and 7.3 months for standard care.

The results highlight mitazalimab’s therapeutic effect and durable efficacy when paired with standard treatment. Additionally, 6-month follow-up data from the 450 µg/kg dose cohort showed an objective response rate of 22.7%, compared to 54.4% for the 900 µg/kg dose. This supports the selection of the 900 µg/kg dose for phase 3 trials.

Søren Bregenholt, CEO of Alligator Bioscience, said: “These 24-month data further validate mitazalimab’s potential to meaningfully impact treatment outcomes for pancreatic cancer patients, and the continued survival and response duration observed in the study reinforce our confidence in mitazalimab’s clinical promise and its potential to reshape the treatment landscape for this aggressive disease.”

Alligator Bioscience is on track to advance mitazalimab toward confirmatory clinical trials, exploring strategic collaborations to accelerate development and maximise its potential as a treatment for pancreatic cancer.